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A novel X-linked mental retardation (XLMR) syndrome was recently identiﬁed, resulting from creatine deﬁciency
in the brain caused by mutations in the creatine transporter gene, SLC6A8. We have studied the prevalence of
SLC6A8 mutations in a panel of 290 patients with nonsyndromic XLMR archived by the European XLMR
Consortium. The full-length open reading frame and splice sites of the SLC6A8 gene were investigated by DNA
sequence analysis. Six pathogenic mutations, of which ﬁve were novel, were identiﬁed in a total of 288 patients
with XLMR, showing a prevalence of at least 2.1% (6/288). The novel pathogenic mutations are a nonsense
mutation (p.Y317X) and four missense mutations. Three missense mutations (p.G87R, p.P390L, and p.P554L)
were concluded to be pathogenic on the basis of conservation, segregation, chemical properties of the residues
involved, as well as the absence of these and any other missense mutation in 276 controls. For the p.C337W
mutation, additional material was available to biochemically prove (i.e., by increased urinary creatine:creatinine
ratio) pathogenicity. In addition, we found nine novel polymorphisms (IVS1+26GrA, IVS7+37GrA, IVS7+87ArG,
IVS7-35GrA, IVS12-3CrT, IVS2+88GrC, IVS9-36GrA, IVS12-82GrC, and p.Y498) that were present in the
XLMR panel and/or in the control panel. Two missense variants (p.V629I and p.M560V) that were not highly
conserved and were not associated with increased creatine:creatinine ratio, one translational silent variant (p.L472),
and 10 intervening sequence variants or untranslated region variants (IVS6+9CrT, IVS7-151_152delGA, IVS7-
99CrA, IVS8-35GrA, IVS8+28CrT, IVS10-18CrT, IVS11+21GrA, IVS12+15CrT, *207GrC, IVS12+32CrA)
were found only in the XLMR panel but should be considered as unclassiﬁed variants or as a polymorphism
(p.M560V). Our data indicate that the frequency of SLC6A8 mutations in the XLMR population is close to that
of CGG expansions in FMR1, the gene responsible for fragile-X syndrome.
Creatine and phosphocreatine play essential roles in the
storage and transmission of phosphate-bound energy
(Walker 1979; Wyss and Kaddurah-Daouk 2000). Hu-
mans maintain their creatine pool by creatine biosyn-
thesis, which involves two enzymes—L-arginine:glycine
amidinotransferase (AGAT; Enzyme Commission [EC]
number 2.1.4.1) and guanidinoacetatemethyltransferase
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(GAMT; EC 2.1.1.2)—as well as nutritional uptake. Cel-
lular transport is of fundamental importance for creatine
homeostasis in tissues void of creatine biosynthesis. The
creatine transporter gene (SLC6A8/CT1/CRTR1 [MIM
300036]) has been mapped to Xq28 (Gregor et al. 1995)
and is a member of the solute-carrier family 6 (neuro-
transmitter transporters). The SLC6A8 gene spans ∼8.4
kb; it consists of 13 exons (GenBank accession number
Z66539) and encodes a protein of 635 amino acids with
a predicted molecular weight of 70 kDa (Sandoval et al.
1996) (ﬁg. 1).
The use of proton magnetic resonance spectroscopy
(H-MRS) resulted in the identiﬁcation of three inborn
errors of metabolism: two creatine biosynthesis errors
(AGAT deﬁciency [MIM 602360] and GAMT deﬁciency
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Figure 1 Mutations and polymorphisms in patientswithXLMR.
Primer sequences were designed speciﬁcally to amplify all exons of the
SLC6A8 gene (and not the SLC6A10 gene, a presumed creatine trans-
porter pseudogene mapped at chromosome 16 [Eichler et al. 1996]),
including short fragments of the ﬂanking intronic sequences. By com-
paring the SLC6A8 and SLC6A10 sequences, we have found that at
least two nucleotide variations were present in all amplicons, conﬁrm-
ing selective ampliﬁcation of the SLC6A8 sequences (data not shown).
PCR reactions were performed with HotStar Taq (Qiagen) in a PE
Applied Biosystems model 9700. Direct sequence analysis was per-
formed on puriﬁed PCR products (Millipore vacufold) by use of
BigDye v3.1 terminators and an ABI 3100 sequence machine (PE Ap-
plied Biosystems). The obtained electropherograms were assembled
and analyzed to identify potential genomic alterations by use of the
Mutation Surveyor software package (SoftGenetics). Sequence variants
were annotated according the guidelines of den Dunnen and Anton-
arakis (2001). On the basis of impaired uptake in ﬁbroblasts, ﬁve
alterations (asterisks [*]) have been proven elsewhere to be mutations.
p.F107del was also found in our XLMR cohort. One novel nonsense
mutation (p.Y317X) is strongly predictive of impaired creatine uptake.
p.M560V is a rare polymorphism, and p.V629I is an unclassiﬁed var-
iant. The implications of the translational silent variant, the IVS var-
iant, and the 3′ UTR variant could not yet be investigated, and these
variants are therefore assigned as “unclassiﬁed.” IVS variants in in-
trons 1, 2, 3, and 4 may have been missed, since only small exon-
ﬂanking parts were included.
[MIM 601240]) and one creatine transport error
(SLC6A8 deﬁciency [MIM 300036]) (Stockler et al.
1994, 1996a, 1996b; Schulze et al. 1997; Bianchi et al.
2000; van der Knaap et al. 2000; Cecil et al. 2001; Item
et al. 2001; Salomons et al. 2001; Bizzi et al. 2002;
deGrauw et al. 2002; Hahn et al. 2002; Salomons et al.
2003). These creatine-deﬁciency syndromes (CDS) share
the almost-complete lack of creatine/phosphocreatine in
the brain, as measured by in vivo H-MRS. Metabolite
measurements in urine and plasma are indicative of the
speciﬁc disorders (e.g., in SLC6A8-deﬁcient males, the
creatine:creatinine [Cr:Crn] ratio is increased in urine,
and guanidinoacetate is increased in urine and plasma
of GAMT-deﬁcient patients). Characteristic in the clin-
ical presentation of all CDS are mental retardation, ex-
pressive speech and language delay, and epilepsy (vary-
ing from intractable seizures in GAMT-deﬁcient patients
to mild epileptic or febrile seizures in AGAT-deﬁcient
and transporter-deﬁcient patients). GAMT-deﬁcient pa-
tients and transporter-deﬁcient patients may show au-
tistic behavior; in GAMT-deﬁcient patients with a severe
phenotype, (extra)pyramidal symptoms are present (Salo-
mons et al. 2003; Stromberger et al. 2003). Female car-
riers of SLC6A8 mutations may have learning disabili-
ties and/or behavioral problems.
In Western countries, mental retardation (MR) affects
2%–3% of the general population (Chelly and Mandel
2001). For the majority of the cases of inherited MR,
the genetic cause has not yet been elucidated. The larger
number of males than females in the MR population
(∼70%) suggests a high contribution of X-linked dis-
orders. X-linked mental retardation (XLMR) is esti-
mated to account for 5%–12% of all cases of MR, with
a relatively large (2%) contribution of fragile-X syn-
drome (fraX) (Herbst and Miller 1980; de Vries et al.
1997). The fact that 115 SLC6A8-deﬁcient families (ﬁve
families in one metropolitan area) have been identiﬁed
in the 2 years after the ﬁrst recognition of this disorder
suggests a high incidence of creatine transporter deﬁ-
ciency in the Western population. Two prominent fea-
tures of SLC6A8 deﬁciency are MR and X-linked in-
heritance of the disease. We therefore investigated by
DNA sequence analysis the prevalence of SLC6A8 de-
fects in a panel of 290 unrelated families of the European
XLMRConsortium (European XLMRConsortiumWeb
site). Families are included in this panel if at least two
males in the family are affected. Informed consent has
been obtained from the parents or caretakers of the af-
fected males. Of the 290 cases, 2 were excluded from
this study, since we were unable to amplify, by PCR,
DNA sequences of the SLC6A8 gene and of two auto-
somal genes, because of the poor quality of the DNA.
In addition, DNAs of 276 healthy controls were similarly
analyzed.
In the European XLMR panel, seven novel nucleotide
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Table 1
Nucleotide Changes in SLC6A8 in the XLMR Panel
Genomic Mutation cDNA Mutation Deduced Effect Family
g.2933GrA c.259GrA p.G87Ra T31
g.4533_4535delCTT c.319_321delCTT p.F107dela T115
g.7400_7401insA c.950_951insA p.Y317stopa P66
g.7461CrG c.1011CrG p.C337Wa N87
g.8032CrT c.1169CrT p.P390La T132
g.8883CrT c.1661CrT p.P554La D11
g.8900ArG c.1678ArG p.M560Vb P18
g.9291GrA c.1885GrA p.V629Ic N67
g.8467GrA c.1416GrA p.L472c 1 family
IVS69CrT ND ND 1 family
IVS7-151_152delGA ND ND 1 family
IVS7-99CrA ND ND 1 family
IVS828CrT ND ND 1 family
IVS8-35GrA ND ND 1 family
IVS10-18CrT ND ND 1 family
IVS1121GrA ND ND 1 family
IVS1215CrT ND ND 1 family
*207GrC ND ND 1 family
IVS1232CrA ND ND 1 family
NOTE.—The SLC6A8 nucleotide changes shown in this table were not found
in the 276 controls or in the human EST database. ND p not determined.
a Pathogenic mutation.
b Polymorphism.
c Unclassiﬁed variant.
substitutions in the ORF of SLC6A8 were encountered:
six missense variations/mutations and one insertion re-
sulting in an immediate nonsense codon. In addition,
one known pathogenic single–amino acid deletion was
found. Furthermore, one translational silent change,
eight intervening sequence (IVS) variants, and one sub-
stitution in the 3′ UTR were detected—none of which
were found in either the 276 controls or the human EST
database (table 1; ﬁg. 1).
In DNA of the index patient of family T115, a deletion
of 3 bp (c.319_321delCTT) in SLC6A8 was detected,
which results in the loss of phenylalanine at position
p.107 (p.F107del). The mutation is located in a short
repeat of two phenylalanines in exon 2. This repeat is
part of transmembrane-spanning domain (TM) II, which
is highly conserved among all known creatine trans-
porters (i.e., bovine, rat, rabbit, marbled electric ray, and
mouse [see ﬁg. 2]) and within the Na- and Cl-depen-
dent neurotransmitter transporter family. The mutation
segregates within the family (ﬁg. 3A). SLC6A8 F107del
was previously reported in an unrelated family (de-
Grauw et al. 2002) (ﬁg. 1). The index male of that family
showed impairment of creatine uptake in ﬁbroblasts.
The following observations indicate that p.F107del is
pathogenic: (1) p.F107 is highly conserved between spe-
cies; (2) p.F107 is located in a conserved area within its
solute carrier family; (3) F107del segregates with the
XLMR phenotype; (4) the mutation was detected in an
unrelated family with SLC6A8 deﬁciency; (5) urine of
affected males with this mutation showed an increased
Cr:Crn ratio, a hallmark of this disease; and (6) ﬁbro-
blasts with this deletion are impaired in creatine uptake.
In DNA of the index patient of family P66, an insertion
of adenosine at position c.951 in exon 6 (c.950_951insA)
of the SLC6A8 gene was found. This mutation predicts
a premature stop (p.Y317X) that results in a truncated
protein of 316 amino acids that lacks 319 amino acids
of the C-terminus, including the putative TM VII–XII of
SLC6A8 (ﬁg. 2). The mutation most likely results in an
unstable and/or inappropriately folded protein that is
completely inactive. Indeed, two other nonsense muta-
tions in the SLC6A8 gene (p.R514X and p.Y262X) (ﬁg.
1) have been shown to impair creatine uptake and are
pathogenic.
In DNA of the index patient of family T31, the tran-
sition GrA at position c.259 in the SLC6A8 gene was
found. This transition results in the substitution p.G87R.
The mutation is located in a short repeat of three glycines
in exon 1. This repeat is located between the putative
TM I and II in a small intracellular loop that is highly
conserved among all known creatine transporters and
within the neurotransmitter transporter family SLC6
(ﬁg. 2). The mutation results in the substitution of the
nonpolar and neutral glycine for the polar and basic
arginine. The highly conserved nature of p.G87 and the
clear difference in the chemical properties of the wild-
type and mutant amino acids indicate that the p.G87R
mutation is pathogenic. Because no additional biological
Figure 2 Multiple-sequence alignment with hierarchical clustering among the SLC6A8 proteins of different species and the superfamily
of neurotransmitter transporters. The SLC6A8 protein sequence is shown for the following species: Homo sapiens (A8), Rattus norvegicus (RN),
Mus musculus (MM), Bos taurus (BT), Oryctolagus cuniculus (OC), and Torpedo marmorata (TM). SLC6A8 genes were identiﬁed by a protein
blast (BLASTP). Alignment was determined by the ClustalW program; the SLC6A8 proteins that were used for this analysis were the ones
identiﬁed by the BLASTP search to be most related to the Homo sapiens SLC6A8 protein. All were saved in FASTA format. The BOXSHADE
program was used to visualize identical amino acids (highlighted in black) and functionally conserved amino acids (gray). Functionally conserved
amino acids are classiﬁed as follows: V, I, L, and M; D, E, Q, and N; F, Y, and W; G, S, T, P, and A; and K, R, and H. The codes A1–A14
represent neurotransmitter transporters SLC6A1–SLC6A14 (A1 p GABA1, A2 p noradrenaline, A3 p dopamine, A4 p serotonine, A5 p
glycine2, A6 p taurine, A7 p proline, A9 p glycine 1, A11 p GABA3, A12 p betaine/GABA, A13 p GABA2, and A14 p ATB0). In the
protein sequence of A5, certain amino acids (20–46, 51–93, 116–127, 143–152, and 168–184) were cut out, because these stretches occur only
in SLC6A5 and would make the ﬁgure disorganized. TMI–TMXII p putative transmembrane domain, predicted by ExPASy (Swiss-Prot
S6A8_Human P48029);p putative cAMP-PK phosphorylation site (2#); p putative N-glycosylation sites (3#);p putative Leu zipper
motif (4#).
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materials (e.g., ﬁbroblasts or urine) were available, the
pathogenicity could not be studied at the biochemical
level or by H-MRS of the brain.
In two affected males of family N87, the transversion
CrG at SLC6A8 c.1011 was found, resulting in the sub-
stitution p.C337W. C337 is located in the intracellular
loop between TM VI and VII and is highly conserved (ﬁg.
2). The substitution of cysteine by tryptophan is highly
signiﬁcant: cysteine is polar and weakly acidic, and the
sulfhydryl group is often involved in protein folding by
forming disulﬁde links, whereas tryptophan is a nonpo-
lar and neutral amino acid, with a very rigid cyclic struc-
ture. The patients’ sister was a carrier of the p.C337W
mutation (ﬁg. 3B). In urine of the two affected males, an
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Figure 3 Pedigree charts of families in which segregation could be studied. (For designation of the variants, see table 1.)
increased Cr:Crn ratio was found, a biochemical hall-
mark of SLC6A8 deﬁciency. These data indicate that the
p.C337W is pathogenic.
In DNA of the index patient of family T132, a tran-
sition of c.1169CrT was detected, resulting in the sub-
stitution p.P390L. The residue P390 is located in the ex-
tracellular loop betweenTMVII andVIII and is conserved
in all known SLC6 family members, except for the sero-
tonine transporter (ﬁg. 2). The p.P390L substitution may
have a signiﬁcant effect on correct protein folding. An af-
fected brother of the index patient also had the p.P390L
substitution (ﬁg. 3C). Therefore, we consider p.P390L
a pathogenic mutation. It is unfortunate that, because
of the unavailability of ﬁbroblasts or urine, the patho-
genicity could not be studied at the biochemical level or
by H-MRS of the brain.
In DNA of the index patient of family D11, a transition
of c.1661CrTwas detected in exon 12 of SLC6A8,which
resulted in the substitution p.P554L. P554 is a residue of
the extracellular loop between TMXI andXII. The region
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of TM IX–XI is expected to harbor the determinants of
substrate speciﬁcity. The residue p.P554 is highly con-
served (see ﬁg. 2). The effect of a substitution of proline
by leucine was discussed above. The p.P554L mutation
segregates with the clinical phenotype within the family
(ﬁg. 3D). Thus, p.P554L is pathogenic. As discussed
above, because of the lack of appropriate biological ma-
terial from the affected males, the pathogenicity could not
be studied at the biochemical or clinical level.
In DNA of the index patient of family N67, a GrA
transition was detected at SLC6A8 c.1885, which resulted
in the substitution p.V629I in exon 13. The nonsynon-
ymous substitution is located in a short repeat of four
valines in the intracellular C-terminus of the creatine
transporter protein (ﬁg. 2). This residue is conserved in
the creatine transporters between species but not among
the SLC6 family members. Moreover, both valine and
isoleucine are members of the same group of aliphatic
amino acids, and, therefore, no change of chemical prop-
erties is predicted. The p.V629Imutation was also present
in the affected brother (ﬁg. 3E). Cr:Crn ratios in urine
were within the low normal range (index patient and
brother 0.001; control values 0–0.3). It is not known
whether mutations in speciﬁc SLC6A8 regions could alter
the function, stability, or trafﬁcking of the protein, as is
described for SLC6A2 (Bauman and Blakely 2002) and
SLC6A13 (Brown et al. 2003). The c.1885GrAtransition
was not found in 276 controls and 95 ESTs. p.V629I is
currently considered to be an unclassiﬁed variant.
In DNA of the index patient of family P18, an ArG
transition was found in SLC6A8 at c.1678 in exon 12,
resulting in the substitution p.M560V. The substitution
was also present in the affected brother of the index
patient. The mother is a carrier of the transition (ﬁg.
3F). p.M560 is conserved in rat, rabbit, and mouse cre-
atine transporter but not in bovine (Val), marbled elec-
tric ray (Ile), or other members of the SLC6 family (ﬁg.
2). The p.M560V mutation was not found in 276 con-
trol chromosomes. However, ﬁbroblasts of the patient
are not deﬁcient in creatine uptake, and, in the H-MRS
of the brain, the creatine signal was present. Therefore,
we conclude that p.M560V is a rare polymorphism.
Whether any of the above-mentioned silent, IVS, and 3′
UTR variants (table 1) are disease causing or just rep-
resent rare polymorphisms remains to be investigated.
The absence of missense mutations in 276 control
chromosomes (appendix A) reduces the chance to !1%
for a missense mutation to be a polymorphismwith 80%
power (Collins and Schwartz 2002). The size of the con-
trol population is rather small to provide conclusive in-
formation on the nature of a speciﬁc missense mutation
found in the equal-sized XLMR population. On the
other hand, the number of missense mutations differs
signiﬁcantly between the patient group and control
groups (6/288 versus 0/276; Fisher’s exact test P value
p .03).
We have identiﬁed 6 pathogenic mutations in 288 pa-
tients. This means a prevalence of 2.1% SLC6A8-deﬁ-
cient patients in this XLMR panel. This may be an un-
derestimate, since we were able to investigate only 93%
of the coding sequence in 288 patients (the complete
coding sequence in 180 patients and, overall, 80% of
the coding sequence in the remaining 108 patients). In
addition, some of the unclassiﬁed variants ( ) maynp 11
prove to be pathogenic.
The presented results were calculated on the basis of
our ﬁndings in a group of 288 patients who were pre-
selected for suspected X-linked inheritance of MR. Cur-
rently, collaboration is being initiated to study the con-
tribution of SLC6A8 deﬁciency in males with MR but
without molecular defects in the FMR1 gene (i.e., fraX
negative).
Throughout exons 1–13 of the coding region of the
SLC6A8 gene, 14 previously reported and novel sequence
variants have been identiﬁed. Mutation types include
three nonsense mutations, two single–amino acid dele-
tions in four families, one large deletion, four missense
mutations, one combined missense/splice-site mutation,
one unclassiﬁed variant (missense type), one translation-
al silent mutation with unknown consequence, and one
missense-type polymorphism. Although several muta-
tions have been identiﬁed already, there is no indication
of a recurrent mutation or a mutation-sensitive/-prone
site (ﬁg. 1).
Knockout-mouse models and clinical trials may result
in a better understanding of the disorder and in appro-
priate treatment protocols for both affected males and
females. The authors suggest that male patients with
MR, autistic behavior, epilepsy, and/or expressive speech
and language delay should be tested for creatine-deﬁ-
ciency disorders. Screening could be based on metabolite
measurement of urine, H-MRS of the brain, and/or mu-
tational analysis by direct sequencing of the gene(s).
Functional tests could prove the biochemical defect and
should include tests for AGAT and GAMT enzyme ac-
tivity or creatine uptake into lymphoblasts or ﬁbroblasts,
respectively. SLC6A8 deﬁciency may contribute, to-
gether with fraX, to MR in an extensive proportion of
males with nonsyndromic XLMR of unknown cause.
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Appendix A
Polymorphisms in the SLC6A8 Gene
The anonymous DNAs of unaffected males were
kindly provided by the Departments of Human Genetics
of the VU University Medical Center in Amsterdam, the
University Medical Center in Nijmegen, and the Uni-
versity Medical Center in Leiden.
SLC6A8 Polymorphisms in Controls and Patients with
XLMR
IVS126GrA
IVS737GrA
IVS787ArG
IVS7-35GrA
IVS12-3CrT
c.1494CrT: p.Y498
SLC6A8 Polymorphisms in Controls Only
IVS288GrC
IVS9-36GrA
IVS12-82GrC
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